Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Cupissol

Showing results (31-40 of 78) with videos related to

Pageof 8
Sort By:
Bulletin Du Cancer|August 1, 1996
[Validation of a new interactive software monitoring a controlled-flow infusion pump for cisplatin dosage regimen adjustment]D Cupissol, J Brès, C Gestin-Boyer, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2001
Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancerM Boucaud, F Pinguet, S Poujol, et al.
Journal of Pharmaceutical Sciences|December 1, 1993
Evaluation of the bioequivalence of tablet and capsule formulations of granisetron in patients undergoing cytotoxic chemotherapy for malignant diseaseD Cupissol, F Bressolle, L Adenis, et al.
Chest|January 30, 1999
Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancerJ L Pujol, T Lafontaine, X Quantin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 1997
Four-step high-dose sequential chemotherapy with hematopoietic progenitor-cell support as induction treatment for patients with solid tumorsS Culine, M Fabbro, C Assens, et al.
Presse Medicale (Paris, France : 1983)|July 11, 1987
[Treatment of epithelial cancer of the ovary. In favor of primary radical and regional surgery before chemotherapy and radiotherapy]H Joyeux, B Saint-Aubert, M C Gouttebel, et al.
Comptes Rendus Des Seances De La Societe De Biologie Et De Ses Filiales|January 1, 1989
[Prevention of cisplatin nephrotoxicity in cancer: adjusting the dosage with a computerized chrono-pump]C Gestin-Boyer, C René, D Cupissol, et al.
Cancer|November 15, 1996
Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatinM G Kris, L X Cubeddu, R J Gralla, et al.
Comptes Rendus Des Seances De La Societe De Biologie Et De Ses Filiales|January 1, 1993
[Ultradian variations of interleukin-1 beta concentration (IL-1 beta), interferon gamma (IFN-gamma) and soluble IL-2 receptors (RIL-2) in healthy volunteers humen]D Bouayad-Amine, D Cupissol, J Nougier-Soule, et al.
Cancer Chemotherapy and Pharmacology|February 9, 2000
Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal functionC Massari, S Brienza, M Rotarski, et al.
Pageof 8

Showing results (31-40 of 78) with videos related to

Sort By:
Pageof 8
Bulletin Du Cancer|August 1, 1996
[Validation of a new interactive software monitoring a controlled-flow infusion pump for cisplatin dosage regimen adjustment]D Cupissol, J Brès, C Gestin-Boyer, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2001
Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancerM Boucaud, F Pinguet, S Poujol, et al.
Journal of Pharmaceutical Sciences|December 1, 1993
Evaluation of the bioequivalence of tablet and capsule formulations of granisetron in patients undergoing cytotoxic chemotherapy for malignant diseaseD Cupissol, F Bressolle, L Adenis, et al.
Chest|January 30, 1999
Neoadjuvant etoposide, ifosfamide, and cisplatin followed by concomitant thoracic radiotherapy and continuous cisplatin infusion in stage IIIb non-small cell lung cancerJ L Pujol, T Lafontaine, X Quantin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 24, 1997
Four-step high-dose sequential chemotherapy with hematopoietic progenitor-cell support as induction treatment for patients with solid tumorsS Culine, M Fabbro, C Assens, et al.
Presse Medicale (Paris, France : 1983)|July 11, 1987
[Treatment of epithelial cancer of the ovary. In favor of primary radical and regional surgery before chemotherapy and radiotherapy]H Joyeux, B Saint-Aubert, M C Gouttebel, et al.
Comptes Rendus Des Seances De La Societe De Biologie Et De Ses Filiales|January 1, 1989
[Prevention of cisplatin nephrotoxicity in cancer: adjusting the dosage with a computerized chrono-pump]C Gestin-Boyer, C René, D Cupissol, et al.
Cancer|November 15, 1996
Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatinM G Kris, L X Cubeddu, R J Gralla, et al.
Comptes Rendus Des Seances De La Societe De Biologie Et De Ses Filiales|January 1, 1993
[Ultradian variations of interleukin-1 beta concentration (IL-1 beta), interferon gamma (IFN-gamma) and soluble IL-2 receptors (RIL-2) in healthy volunteers humen]D Bouayad-Amine, D Cupissol, J Nougier-Soule, et al.
Cancer Chemotherapy and Pharmacology|February 9, 2000
Pharmacokinetics of oxaliplatin in patients with normal versus impaired renal functionC Massari, S Brienza, M Rotarski, et al.
Pageof 8